iScience (Mar 2023)
Tocilizumab-treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants
- Camille Chauvin,
- Laurine Levillayer,
- Mathilde Roumier,
- Hubert Nielly,
- Claude Roth,
- Anupama Karnam,
- Srinivasa Reddy Bonam,
- Anne Bourgarit,
- Clément Dubost,
- Aurore Bousquet,
- Sébastien Le Burel,
- Raphaële Mestiri,
- Damien Sene,
- Joris Galland,
- Marc Vasse,
- Matthieu Groh,
- Mathilde Le Marchand,
- Camille Vassord-Dang,
- Jean-François Gautier,
- Nhan Pham-Thi,
- Christiane Verny,
- Bruno Pitard,
- Cyril Planchais,
- Hugo Mouquet,
- Richard Paul,
- Etienne Simon-Loriere,
- Jagadeesh Bayry,
- Laurent Gilardin,
- Anavaj Sakuntabhai
Affiliations
- Camille Chauvin
- Institut Pasteur, Université de Paris, Functional Genetics of Infectious Diseases Unit, Department of Global Health, 75015 Paris, France; Centre National de la Recherche Scientifique (CNRS), UMR2000, Paris Cedex 15, France
- Laurine Levillayer
- Institut Pasteur, Université de Paris, Functional Genetics of Infectious Diseases Unit, Department of Global Health, 75015 Paris, France; Centre National de la Recherche Scientifique (CNRS), UMR2000, Paris Cedex 15, France
- Mathilde Roumier
- Service de Médecine Interne, Hôpital Foch, 92151 Suresnes, France
- Hubert Nielly
- Service de Médecine Interne, Hôpital d’Instruction des Armées Bégin, 94160 Saint Mandé, France
- Claude Roth
- Institut Pasteur, Université de Paris, Functional Genetics of Infectious Diseases Unit, Department of Global Health, 75015 Paris, France; Centre National de la Recherche Scientifique (CNRS), UMR2000, Paris Cedex 15, France
- Anupama Karnam
- Institut National de la Santé et de la Recherche Médicale, Centre de Recherche des Cordeliers, Sorbonne Université, Université de Paris, Paris, 75006, France
- Srinivasa Reddy Bonam
- Institut National de la Santé et de la Recherche Médicale, Centre de Recherche des Cordeliers, Sorbonne Université, Université de Paris, Paris, 75006, France
- Anne Bourgarit
- Hôpital Jean Verdier, HUPSSD, AP-HP, 93140 Bondy, France; Sorbonne Paris-Nord University (Paris 13), 93000 Bobigny, France; Inserm, UMR 1135 CIMI, 75013 Paris, France
- Clément Dubost
- Service de réanimation, Hôpital militaire Bégin, 94120 Saint Mandé, France; Université Paris-Saclay, ENS Paris-Saclay, CNRS, Centre Borelli, 91190, Gif-sur-Yvette, France
- Aurore Bousquet
- Département des laboratoires, Hôpital militaire Bégin, 94120 Saint Mandé, France
- Sébastien Le Burel
- Service de Médecine Interne, Hôpital d’Instruction des Armées Bégin, 94160 Saint Mandé, France
- Raphaële Mestiri
- Service de Médecine Interne, Hôpital d’Instruction des Armées Bégin, 94160 Saint Mandé, France
- Damien Sene
- Département de médecine interne, Hôpital Lariboisière, Université de Paris (Diderot), AP-HP, 75010 Paris, France
- Joris Galland
- Département de médecine interne, Hôpital Lariboisière, Université de Paris (Diderot), AP-HP, 75010 Paris, France
- Marc Vasse
- Laboratoire de Biologie Médicale, Hôpital Foch, 92151 Suresnes, France; UMRS-1176, Le Kremlin Bicêtre, France
- Matthieu Groh
- Service de Médecine Interne, Hôpital Foch, 92151 Suresnes, France
- Mathilde Le Marchand
- Department of Clinical Research and Innovation, Foch Hospital, 40 rue Worth, 92150 Suresnes, France
- Camille Vassord-Dang
- Department of Clinical Research and Innovation, Foch Hospital, 40 rue Worth, 92150 Suresnes, France
- Jean-François Gautier
- Departement of Diabetes and Endocrinology, Hôpital Lariboisière, APHP, and INSERM U1138 Paris, France; Université de Paris, 75006 Paris, France
- Nhan Pham-Thi
- Unité de Neurophysiologie du Stress, Département des Neurosciences, Institut de Recherche Biomédicale des Armées (IRBA), BP 73 91223 Brétigny sur Orge Cedex, France
- Christiane Verny
- Unité de Neurophysiologie du Stress, Département des Neurosciences, Institut de Recherche Biomédicale des Armées (IRBA), BP 73 91223 Brétigny sur Orge Cedex, France
- Bruno Pitard
- Nantes Université, INSERM, CNRS, Immunology and New Concepts in ImmunoTherapy, INCIT,UMR 1302, F-44000 Nantes, France
- Cyril Planchais
- Institut Pasteur, Université de Paris, Humoral Immunology Unit, Department of Immunology, 75015 Paris, France
- Hugo Mouquet
- Institut Pasteur, Université de Paris, Humoral Immunology Unit, Department of Immunology, 75015 Paris, France
- Richard Paul
- Institut Pasteur, Université de Paris, Functional Genetics of Infectious Diseases Unit, Department of Global Health, 75015 Paris, France; Centre National de la Recherche Scientifique (CNRS), UMR2000, Paris Cedex 15, France
- Etienne Simon-Loriere
- Institut Pasteur, Université de Paris, G5 Evolutionary Genomics of RNA viruses, 75015 Paris, France
- Jagadeesh Bayry
- Institut National de la Santé et de la Recherche Médicale, Centre de Recherche des Cordeliers, Sorbonne Université, Université de Paris, Paris, 75006, France; Department of Biological Sciences & Engineering, Indian Institute of Technology Palakkad, Palakkad 678623, India
- Laurent Gilardin
- Institut National de la Santé et de la Recherche Médicale, Centre de Recherche des Cordeliers, Sorbonne Université, Université de Paris, Paris, 75006, France; Sorbonne Paris-Nord University (Paris 13), 93000 Bobigny, France; Service de médecine interne, Hôpital Jean Verdier, HUPSSD, AP-HP, 93140 Bondy, France
- Anavaj Sakuntabhai
- Institut Pasteur, Université de Paris, Functional Genetics of Infectious Diseases Unit, Department of Global Health, 75015 Paris, France; Centre National de la Recherche Scientifique (CNRS), UMR2000, Paris Cedex 15, France; International Vaccine Design Center (vDesC), The Institute of Medical Science, The University of Tokyo (IMSUT), Tokyo, Japan; Corresponding author
- Journal volume & issue
-
Vol. 26,
no. 3
p. 106124
Abstract
Summary: Although tocilizumab treatment in severe and critical coronavirus disease 2019 (COVID-19) patients has proven its efficacy at the clinical level, there is little evidence supporting the effect of short-term use of interleukin-6 receptor blocking therapy on the B cell sub-populations and the cross-neutralization of SARS-CoV-2 variants in convalescent COVID-19 patients. We performed immunological profiling of 69 tocilizumab-treated and non-treated convalescent COVID-19 patients in total. We observed that SARS-CoV-2-specific IgG1 titers depended on disease severity but not on tocilizumab treatment. The plasma of both treated and non-treated patients infected with the ancestral variant exhibit strong neutralizing activity against the ancestral virus and the Alpha, Beta, and Delta variants of SARS-CoV-2, whereas the Gamma and Omicron viruses were less sensitive to seroneutralization. Overall, we observed that, despite the clinical benefits of short-term tocilizumab therapy in modifying the cytokine storm associated with COVID-19 infections, there were no modifications in the robustness of B cell and IgG responses to Spike antigens.
